Munafò Marcus R, Shields Alexandra E, Berrettini Wade H, Patterson Freda, Lerman Caryn
University of Bristol, Department of Experimental Psychology, Bristol BS8 ITN, UK.
Pharmacogenomics. 2005 Apr;6(3):211-23. doi: 10.1517/14622416.6.3.211.
This review focuses on the current status of, and future directions for, pharmacogenetic research on nicotine dependence and smoking cessation treatment. Pharmacological treatment involving nicotine replacement therapy and bupropion for nicotine addiction and smoking cessation has been shown to be efficacious when provided in combination with behavioral support. Cessation rates remain somewhat modest, however, and one possibility is that success rates may be enhanced by offering treatments tailored to an individual's genotype. Nonetheless, research on this issue remains in its infancy, and although the scope for individualized treatment tailored to genotype is promising, there are substantial practical, ethical and social considerations that must be addressed before such research is translated into clinical practice.
本综述聚焦于尼古丁依赖和戒烟治疗的药物遗传学研究现状及未来方向。涉及尼古丁替代疗法和安非他酮用于尼古丁成瘾及戒烟的药物治疗，在与行为支持相结合时已被证明是有效的。然而，戒烟率仍较为一般，一种可能性是通过提供针对个体基因型的治疗来提高成功率。尽管如此，关于这个问题的研究仍处于起步阶段，虽然根据基因型进行个体化治疗的前景广阔，但在将此类研究转化为临床实践之前，必须解决大量实际、伦理和社会方面的考量。
